

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Description:	<u>Lovastatin</u>
Cat No. :	458830000; 458830050; 458830250; 458831000
CAS No	75330-75-5
EC No	616-212-7
Molecular Formula	C ₂₄ H ₃₆ O ₅

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use	Laboratory chemicals.
Uses advised against	No Information available

1.3. Details of the supplier of the safety data sheet

Company

UK entity/business name
Fisher Scientific UK
Bishop Meadow Road,
Loughborough, Leicestershire LE11 5RG, United Kingdom

EU entity/business name
Thermo Fisher Scientific
Janssen Pharmaceuticaaan 3a, 2440 Geel, Belgium

E-mail address begel.sdsdesk@thermofisher.com

1.4. Emergency telephone number

For information **US** call: 001-800-227-6701 / **Europe** call: +32 14 57 52 11
Emergency Number **US**:001-201-796-7100 / **Europe**: +32 14 57 52 99
CHEMTREC Tel. No. **US**:001-800-424-9300 / **Europe**:001-703-527-3887

SECTION 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567

Physical hazards

Based on available data, the classification criteria are not met

Health hazards

Skin Sensitization

Category 1 (H317)

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

Carcinogenicity
Reproductive Toxicity

Category 2 (H351)
Category 2 (H361d)

Environmental hazards

Based on available data, the classification criteria are not met

Full text of Hazard Statements: see section 16

2.2. Label elements



Signal Word

Warning

Hazard Statements

H317 - May cause an allergic skin reaction
H351 - Suspected of causing cancer
H361d - Suspected of damaging the unborn child

Precautionary Statements

P302 + P352 - IF ON SKIN: Wash with plenty of soap and water
P362 + P364 - Take off contaminated clothing and wash it before reuse
P201 - Obtain special instructions before use
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical advice/attention

2.3. Other hazards

This product does not contain any known or suspected endocrine disruptors
Toxic to terrestrial vertebrates

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substances

Component	CAS No	EC No	Weight %	GHS Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567
Lovastatin	75330-75-5	616-212-7	>95	Skin Sens. 1 (H317) Carc. 2 (H351) Repr. 2 (H361d)

Full text of Hazard Statements: see section 16

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

SECTION 4: FIRST AID MEASURES

4.1. Description of first aid measures

General Advice	If symptoms persist, call a physician.
Eye Contact	Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get medical attention.
Skin Contact	Wash off immediately with plenty of water for at least 15 minutes. If skin irritation persists, call a physician.
Ingestion	Clean mouth with water and drink afterwards plenty of water. Get medical attention if symptoms occur.
Inhalation	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention if symptoms occur.
Self-Protection of the First Aider	Ensure that medical personnel are aware of the material(s) involved, take precautions to protect themselves and prevent spread of contamination.

4.2. Most important symptoms and effects, both acute and delayed

None reasonably foreseeable. May cause allergic skin reaction. Symptoms of allergic reaction may include rash, itching, swelling, trouble breathing, tingling of the hands and feet, dizziness, lightheadedness, chest pain, muscle pain or flushing

4.3. Indication of any immediate medical attention and special treatment needed

Notes to Physician Treat symptomatically.

SECTION 5: FIREFIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media

Water spray, carbon dioxide (CO₂), dry chemical, alcohol-resistant foam.

Extinguishing media which must not be used for safety reasons

No information available.

5.2. Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors.

Hazardous Combustion Products

Carbon oxides.

5.3. Advice for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Use personal protective equipment as required. Avoid dust formation.

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

6.2. Environmental precautions

Should not be released into the environment.

6.3. Methods and material for containment and cleaning up

Sweep up and shovel into suitable containers for disposal. Keep in suitable, closed containers for disposal.

6.4. Reference to other sections

Refer to protective measures listed in Sections 8 and 13.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Wear personal protective equipment/face protection. Ensure adequate ventilation. Do not get in eyes, on skin, or on clothing. Avoid ingestion and inhalation. Avoid dust formation.

Hygiene Measures

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Keep containers tightly closed in a dry, cool and well-ventilated place. To maintain product quality: Keep refrigerated. Protect from direct sunlight.

Technical Rules for Hazardous Substances (TRGS) 510 Class 11
Storage Class (LGK) (Germany)

7.3. Specific end use(s)

Use in laboratories

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure limits

List source(s):

Biological limit values

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

Derived No Effect Level (DNEL) / Derived Minimum Effect Level (DMEL)

No information available

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

Predicted No Effect Concentration (PNEC)

No information available.

8.2. Exposure controls

Engineering Measures

Ensure adequate ventilation, especially in confined areas.

Wherever possible, engineering control measures such as the isolation or enclosure of the process, the introduction of process or equipment changes to minimise release or contact, and the use of properly designed ventilation systems, should be adopted to control hazardous materials at source

Personal protective equipment

Eye Protection

Wear safety glasses with side shields (or goggles) (European standard - EN 166)

Hand Protection

Protective gloves

Glove material	Breakthrough time	Glove thickness	EU standard	Glove comments
Nitrile rubber	See manufacturers	-	EN 374	(minimum requirement)
Neoprene	recommendations			
Natural rubber				
PVC				

Skin and body protection

Long sleeved clothing.

Inspect gloves before use.

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. (Refer to manufacturer/supplier for information)

Ensure gloves are suitable for the task: Chemical compatibility, Dexterity, Operational conditions, User susceptibility, e.g. sensitisation effects, also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion.

Remove gloves with care avoiding skin contamination.

Respiratory Protection

When workers are facing concentrations above the exposure limit they must use appropriate certified respirators.

To protect the wearer, respiratory protective equipment must be the correct fit and be used and maintained properly

Large scale/emergency use

Use a NIOSH/MSHA or European Standard EN 136 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced

Recommended Filter type: Particulates filter conforming to EN 143

Small scale/Laboratory use

Use a NIOSH/MSHA or European Standard EN 149:2001 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Recommended half mask:- Particle filtering: EN149:2001

When RPE is used a face piece Fit Test should be conducted

Environmental exposure controls

No information available.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical State

Solid

Appearance

White

Odor

No information available

Odor Threshold

No data available

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

Melting Point/Range	175 °C / 347 °F	
Softening Point	No data available	
Boiling Point/Range	No information available	
Flammability (liquid)	Not applicable	Solid
Flammability (solid,gas)	No information available	
Explosion Limits	No data available	
Flash Point	No information available	Method - No information available
Autoignition Temperature	No data available	
Decomposition Temperature	No data available	
pH	No information available	
Viscosity	Not applicable	Solid
Water Solubility	Insoluble	
Solubility in other solvents	No information available	
Partition Coefficient (n-octanol/water)		
Component	log Pow	
Lovastatin	4.26	
Vapor Pressure	No data available	
Density / Specific Gravity	No data available	
Bulk Density	No data available	
Vapor Density	Not applicable	Solid
Particle characteristics	No data available	

9.2. Other information

Molecular Formula	C ₂₄ H ₃₆ O ₅
Molecular Weight	404.54
Evaporation Rate	Not applicable - Solid

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity

None known, based on information available

10.2. Chemical stability

Light sensitive.

10.3. Possibility of hazardous reactions

Hazardous Polymerization	No information available.
Hazardous Reactions	None under normal processing.

10.4. Conditions to avoid

Incompatible products. Excess heat. Avoid dust formation. Protect from light.

10.5. Incompatible materials

Strong oxidizing agents.

10.6. Hazardous decomposition products

Carbon oxides.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Product Information

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

(a) acute toxicity;

Oral

Based on available data, the classification criteria are not met

Dermal

No data available

Inhalation

No data available

Component	LD50 Oral	LD50 Dermal	LC50 Inhalation
Lovastatin	LD50 > 5000 mg/kg (Rat)	-	-

(b) skin corrosion/irritation;

No data available

(c) serious eye damage/irritation;

No data available

(d) respiratory or skin sensitization;

Respiratory

No data available

Skin

Category 1

May cause sensitization by skin contact

(e) germ cell mutagenicity;

No data available

(f) carcinogenicity;

Category 2

Limited evidence of a carcinogenic effect

(g) reproductive toxicity;

Reproductive Effects

Category 2

Product is or contains a chemical which is a known or suspected reproductive hazard.

(h) STOT-single exposure;

No data available

(i) STOT-repeated exposure;

No data available

Target Organs

None known.

(j) aspiration hazard;

Not applicable

Solid

Symptoms / effects, both acute and delayed

Symptoms of allergic reaction may include rash, itching, swelling, trouble breathing, tingling of the hands and feet, dizziness, lightheadedness, chest pain, muscle pain or flushing.

11.2. Information on other hazards

Endocrine Disrupting Properties

Assess endocrine disrupting properties for human health. This product does not contain any known or suspected endocrine disruptors.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Ecotoxicity effects

Contains no substances known to be hazardous to the environment or that are not degradable in waste water treatment plants.

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

12.2. Persistence and degradability

Persistence May persist.

12.3. Bioaccumulative potential

Product has a high potential to bioconcentrate

Component	log Pow	Bioconcentration factor (BCF)
Lovastatin	4.26	No data available

12.4. Mobility in soil

Spillage unlikely to penetrate soil Is not likely mobile in the environment due its low water solubility. Is not likely mobile in the environment due its low water solubility and propensity to bind to soil particles

12.5. Results of PBT and vPvB assessment

No data available for assessment.

12.6. Endocrine disrupting properties

Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors

12.7. Other adverse effects Persistent Organic Pollutant Ozone Depletion Potential

This product does not contain any known or suspected substance
This product does not contain any known or suspected substance

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from Residues/Unused Products Waste is classified as hazardous. Dispose of in accordance with the European Directives on waste and hazardous waste. Dispose of in accordance with local regulations.

Contaminated Packaging Dispose of this container to hazardous or special waste collection point.

European Waste Catalogue (EWC) According to the European Waste Catalog, Waste Codes are not product specific, but application specific.

Other Information Waste codes should be assigned by the user based on the application for which the product was used. Do not empty into drains.

SECTION 14: TRANSPORT INFORMATION

IMDG/IMO Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

ADR Not regulated

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

14.1. UN number
14.2. UN proper shipping name
14.3. Transport hazard class(es)
14.4. Packing group

IATA Not regulated

14.1. UN number
14.2. UN proper shipping name
14.3. Transport hazard class(es)
14.4. Packing group

14.5. Environmental hazards No hazards identified

14.6. Special precautions for user No special precautions required.

14.7. Maritime transport in bulk according to IMO instruments Not applicable, packaged goods

SECTION 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

China, X = listed, U.S.A. (TSCA), Canada (DSL/NDSL), Europe (EINECS/ELINCS/NLP), Australia (AICS), Korea (KECL), China (IECSC), Japan (ENCS), Philippines (PICCS), Taiwan (TCSI), Japan (ISHL), New Zealand (NZIoC), Japan (ISHL). US EPA (TSCA) - Toxic Substances Control Act, (40 CFR Part 710)

Component	CAS No	EINECS	ELINCS	NLP	IECSC	TCSI	KECL	ENCS	ISHL
Lovastatin	75330-75-5	-	-	-	X	X	-	-	X

Component	CAS No	TSCA	TSCA Inventory notification - Active-Inactive	DSL	NDSL	AICS	NZIoC	PICCS
Lovastatin	75330-75-5	-	-	-	-	-	X	-

Legend: X - Listed '-' - Not Listed

KECL - NIER number or KE number (<http://ncis.nier.go.kr/en/main.do>)

Authorisation/Restrictions according to EU REACH Not applicable

Component	CAS No	REACH (1907/2006) - Annex XIV - Substances Subject to Authorization	REACH (1907/2006) - Annex XVII - Restrictions on Certain Dangerous Substances	REACH Regulation (EC 1907/2006) article 59 - Candidate List of Substances of Very High Concern (SVHC)
Lovastatin	75330-75-5	-	-	-

Seveso III Directive (2012/18/EC)

Component	CAS No	Seveso III Directive (2012/18/EC) - Qualifying Quantities for Major Accident Notification	Seveso III Directive (2012/18/EC) - Qualifying Quantities for Safety Report Requirements
Lovastatin	75330-75-5	Not applicable	Not applicable

Regulation (EC) No 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning the export and import of dangerous chemicals

Not applicable

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

Contains component(s) that meet a 'definition' of per & poly fluoroalkyl substance (PFAS)?

Not applicable

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work .

Take note of Directive 94/33/EC on the protection of young people at work

Take note of Dir 92/85/EC on the protection of pregnant and breastfeeding women at work

National Regulations

UK - Take note of Control of Substances Hazardous to Health Regulations (COSHH) 2002 and 2005 Amendment

WGK Classification Water endangering class = 3 (self classification)

15.2. Chemical safety assessment

A Chemical Safety Assessment/Report (CSA/CSR) has not been conducted

SECTION 16: OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3

H317 - May cause an allergic skin reaction

H351 - Suspected of causing cancer

H361d - Suspected of damaging the unborn child

Legend

CAS - Chemical Abstracts Service

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

IECSC - Chinese Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

ENCS - Japanese Existing and New Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

WEL - Workplace Exposure Limit

ACGIH - American Conference of Governmental Industrial Hygienists

DNEL - Derived No Effect Level

RPE - Respiratory Protective Equipment

LC50 - Lethal Concentration 50%

NOEC - No Observed Effect Concentration

PBT - Persistent, Bioaccumulative, Toxic

TWA - Time Weighted Average

IARC - International Agency for Research on Cancer Predicted No Effect Concentration (PNEC)

LD50 - Lethal Dose 50%

EC50 - Effective Concentration 50%

POW - Partition coefficient Octanol:Water

vPvB - very Persistent, very Bioaccumulative

ADR - European Agreement Concerning the International Carriage of Dangerous Goods by Road

IMO/IMDG - International Maritime Organization/International Maritime Dangerous Goods Code

OECD - Organisation for Economic Co-operation and Development

BCF - Bioconcentration factor

ICAO/IATA - International Civil Aviation Organization/International Air Transport Association

MARPOL - International Convention for the Prevention of Pollution from Ships

ATE - Acute Toxicity Estimate

VOC - (Volatile Organic Compound)

Key literature references and sources for data

<https://echa.europa.eu/information-on-chemicals>

Suppliers safety data sheet, Chemadviser - LOLI, Merck index, RTECS

SAFETY DATA SHEET

Lovastatin

Revision Date 06-Oct-2023

Training Advice

Chemical hazard awareness training, incorporating labelling, Safety Data Sheets (SDS), Personal Protective Equipment (PPE) and hygiene.

Use of personal protective equipment, covering appropriate selection, compatibility, breakthrough thresholds, care, maintenance, fit and standards.

First aid for chemical exposure, including the use of eye wash and safety showers.

Creation Date	17-Mar-2015
Revision Date	06-Oct-2023
Revision Summary	SDS sections updated.

This safety data sheet complies with Regulation UK SI 2019/758 and UK SI 2020/1577 as amended.

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text

End of Safety Data Sheet